Whey Protein Fractionation Patents: Top Companies & Trends 2026
- 28.0% concentration at the top. The five leading assignees account for 1,123 of the 4,016 records in scope — a field with a clear head but still room beneath it.
- Filings cooled after a 2019 peak. Output ran from 298 records that year down to 8 in the still-filling 2026 window, with a measured -44% drop from 133 (2021) to 75 (2024).
- Foods and medicinal claims dominate. A23L food/beverage classes touch 51.3% of records and A61K medicinal preparations touch 32.0%, showing fractionation output is claimed mostly as ingredient, not process alone.
Filing growth compares 2021 (133 records) with 2024 (75) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 4,016 records in scope (CR5), not by the ranked leaders only.
What the whey protein fractionation patent record shows
Whey protein fractionation covers the separation of whey into functional components — isolates, lactoferrin, individual protein fractions — using techniques such as ion exchange, membrane separation and controlled denaturation. The 4,016 records captured here span filings from 2015 through the partial 2026 window, drawing on search terms that pair fractionation and isolate language with the process controls that make a fraction commercially usable: ion exchange, lactoferrin recovery, denaturation control, protein selectivity, process yield and functional property claims.
Filing activity peaked in 2019 and has since eased, though the most recent two or three years are understated because publication typically lags filing by around 18 months. Reading the trend past 2024 as a decline would be premature; the dataset's own growth figure covers only the 2021-to-2024 span.
Filing trend and technology composition
The two views below are the backbone of the landscape: how filing volume has moved year over year, and which IPC subclasses carry the claim weight once a fractionation patent is filed.
A 2019 peak, then a measured pullback
Annual records rose from 209 in 2017 to a peak of 298 in 2019, then eased to 133 by 2021 and 75 by 2024 — a -44% move over that three-year span. Years from 2025 onward are still filling in as publication catches up, so treat the tail of the chart as a floor, not a forecast.
Food and medicinal classes carry the most weight
A23L (foods and non-alcoholic beverages) appears on 51.3% of the 4,016 records, well ahead of A61K medicinal preparations at 32.0%, A23C dairy products at 28.7% and A23J proteins/food peptides at 28.6%. Because a single record can carry several IPC classes, these shares add to more than 100%; the smaller downstream classes — A61P therapeutic activity (12.2%), C07K peptides/proteins (10.0%), C12P fermentation (7.3%) and C12N microorganisms (6.5%) — mark where fractionation output is being routed into pharma and biotech applications rather than food formulation alone.
Shares are the percentage of the 4,016 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Whey Protein Fractionation with Eureka
This page is one run against one query. Ask Eureka your own question about whey protein fractionation and every answer comes back with the patent numbers behind it.
Try EurekaA representative filing and the most-cited anchors
High-foaming, stable modified whey protein isolate (US20020061359A1)
A modified whey protein isolate having the ability to fully replace egg whites in many food applications requiring foaming is prepared by a process which involves heat treating to obtain a unique balance of overrun and foam stability properties. The process entails heating an aqueous solution of whey protein isolate at from 70 to 85°C, and can include holding at this temperature and pH adjustment prior to heating to obtain the desired properties. Food mixes employing the modified whey protein isolate and processes for making food products employing the modified whey protein isolate are also provided.Filed by Baker, Lois A. — published 2002-05-23. Its heat-treatment window is a useful reference point for functional-property claims still being filed today.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6596298B2 | Fast dissolving orally comsumable films | 611 |
| 2 | WO2013096420A1 | Methods for purifying steviol glycosides and uses of the same | 352 |
| 3 | US6923981B2 | Fast dissolving orally consumable films | 315 |
| 4 | US20170119032A1 | High intensity sweeteners | 256 |
| 5 | US20030224090A1 | Snacks of orally soluble edible films | 255 |
| 6 | WO2001070194A1 | Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent | 246 |
| 7 | US20010022964A1 | Fast dissolving orally consumable films | 229 |
| 8 | US7067116B1 | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active age… | 215 |
| 9 | US20050003048A1 | Electrolyte-containing orally soluble films | 211 |
| 10 | US20170341942A1 | Methods and systems for large scale carbon dioxide utilization from lake KIVU via a co2 industrial utilizatio… | 206 |
Citation counts favour older filings that have had more time to accumulate references — read them as a signal of influence within this searched corpus, not as a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once concentration, timing and classification are read together.
A clear head, not a monopoly
The leader alone holds 306 records and the fifth-ranked assignee 178, yet the top five together still account for only just over a quarter of the field. That leaves the bulk of filings spread across a long tail of single- and few-filing entrants — a structure where a well-drafted process claim can still carve out room.
Volume has eased since the 2019 peak
Filings rose to 298 in 2019 before easing through the early 2020s. The -44% move from 2021 to 2024 is the only complete-year comparison the data supports; years closer to the 2026 cut-off are still filling in as publications catch up to filings made 12-18 months earlier.
Ingredient claims outnumber pure process claims
Food and beverage classification touches roughly half of all records, while medicinal-preparation classification touches nearly a third — evidence that most fractionation patents are drafted around what the fraction becomes, not the separation step in isolation. Downstream biotech classes (C07K, C12P, C12N) sit in the single digits to low teens, marking the smaller but real pharma-adjacent slice of the field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to whey protein fractionation, with the prior art for and against each one.
Who is filing, and where the gate sits
Filing volume concentrates among dairy and ingredient majors, with co-filing patterns pointing to a small number of steady collaborations rather than a broad web of joint filings.
The leading filer sets the pace
The top-ranked assignee holds more than 70% more records than the fifth-place company (178), giving it the deepest claim coverage in the ranking. That gap narrows quickly further down the list, where tenth place holds 77 records — under half the leader's count.
Recent activity is thin across the board
Latest-year filing counts among the tracked assignees are small in absolute terms — a handful of records each — so percentage swings should be read against that low base rather than as a shift in strategy. Several established filers show flat or declining latest-year counts, consistent with the broader post-2019 pullback.
Collaboration is concentrated, not widespread
Only ten co-assignee pairs are identified in this dataset, and the strongest single pairing accounts for 96 joint records — far ahead of the next pairings at 34 and 25. Most assignees in the ranking file independently.
| Assignee | Recent year | YoY |
|---|---|---|
| Nestec SA (Switzerland) | 3 | +50% |
| Fonterra Co-operative Group Ltd | 1 | -83% |
| The Coca-Cola Company | 1 | 0% |
| Arla Foods amba | 0 | -100% |
| Nestle Technology | 0 | — |
| N.V. Nutricia | 0 | — |
| PureCircle Sdn Bhd | 0 | -100% |
| FIRMENICH INC | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking or identifying open claim space.
Map freedom-to-operate against the dense core
A23L, A61K, A23C and A23J together cover the bulk of records. Any new filing that touches food-application claims for a fraction should be checked against this core before drafting.
Run a freedom-to-operate checkWatch the leader-to-tail gap for acquisition or licensing signals
A top assignee holding 306 records against a long tail of small filers is a classic setup for licensing-in or bolt-on acquisition activity in adjacent sub-areas.
Track assignee activityProbe the under-claimed sub-areas directly
Membrane-based selectivity tuning and enzymatic yield optimisation sit outside the densest classes and warrant a focused prior-art pull before committing R&D spend.
Explore white space with EurekaCommon questions on whey protein fractionation patents
One assignee leads the ranked list with 306 records, noticeably ahead of the fifth-place company at 178 and tenth place at 77. The top five assignees combined hold 1,123 records, which is 28.0% of the 4,016 records in scope — a meaningful lead but not a dominant monopoly, since the remaining 72% is spread across a long tail of smaller filers. Anyone assessing competitive position should look at both the leader's individual count and how quickly the ranking thins out below fifth place.
Filing volume peaked in 2019 at 298 records and has eased since, with a documented -44% change from 133 records in 2021 to 75 in 2024. That said, years closer to the 2026 data cut-off are understated because patent publication typically lags filing by around 18 months, so the most recent one or two years should not be read as a genuine drop-off yet. The safest complete-year comparison the data supports is the 2021-to-2024 span.
Food and non-alcoholic beverage classification (IPC A23L) touches 51.3% of the 4,016 records, making it the single most common classification, followed by medicinal preparations (A61K) at 32.0%, dairy products (A23C) at 28.7% and proteins/food peptides (A23J) at 28.6%. Because a record can carry multiple IPC codes, these percentages overlap rather than sum to 100%. The pattern shows most patents are drafted around the food or medicinal end-use of the fractionated protein rather than the separation process in isolation.
The denser core classes are food/beverage, medicinal, dairy and protein/peptide classification; sub-areas such as membrane-based selectivity tuning, enzymatic yield optimisation and low-temperature denaturation control for foaming applications sit further from that core and show comparatively thinner claim density. Co-filing activity is also concentrated in only ten identified pairs, suggesting most of the field files independently rather than through joint ventures. A first claim in an under-claimed branch would typically pair a specific separation parameter (temperature, pH, membrane pore size) with a named functional outcome, rather than claiming the fraction itself broadly.
US20020061359A1 covers a modified whey protein isolate produced by heat-treating an aqueous solution at 70 to 85°C, with optional holding time and pH adjustment, to achieve a specific balance of foam overrun and stability suitable for replacing egg whites. It is a representative filing rather than the field's broadest patent, but its specific temperature window and functional target (foaming, egg-white replacement) are useful reference points when checking whether a new heat-treatment process for foaming isolates falls inside or outside its claimed range. Any process claiming a similar temperature band and foaming outcome should be checked against it directly rather than assumed clear.
Research Whey Protein Fractionation in depth with Eureka
Go past this page: query the whole whey protein fractionation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.